{"id":"jr-141-or-idursulfase","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Antibody formation"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hunter syndrome (mucopolysaccharidosis II) is caused by deficiency of the iduronate-2-sulfatase enzyme, leading to accumulation of glycosaminoglycans in tissues. JR-141 is an enzyme replacement therapy that provides the missing enzyme, enabling degradation of accumulated substrates. The drug is formulated to cross the blood-brain barrier and address both systemic and central nervous system manifestations of the disease.","oneSentence":"JR-141 is a recombinant idursulfase enzyme that replaces deficient iduronate-2-sulfatase to break down glycosaminoglycans in Hunter syndrome.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:49:04.011Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hunter syndrome (mucopolysaccharidosis II, MPS II) with central nervous system involvement"}]},"trialDetails":[{"nctId":"NCT04573023","phase":"PHASE3","title":"A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"JCR Pharmaceuticals Co., Ltd.","startDate":"2022-02-14","conditions":"Mucopolysaccharidosis II","enrollment":86}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":170,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"JR-141 or Idursulfase","genericName":"JR-141 or Idursulfase","companyName":"JCR Pharmaceuticals Co., Ltd.","companyId":"jcr-pharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JR-141 is a recombinant idursulfase enzyme that replaces deficient iduronate-2-sulfatase to break down glycosaminoglycans in Hunter syndrome. Used for Hunter syndrome (mucopolysaccharidosis II, MPS II) with central nervous system involvement.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}